Ask Warren

GFC Life Science

388610 · KOSDAQ · ₩388610 · 지에프씨생명과학

₩4,545▼ ₩125 (2.68%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −75.56%
Market cap
₩24B
Enterprise value
₩27B
P/E
22.5×
P/B
1.0×
Dividend yield
0.0%
ROE
4.3%
Net margin
5.6%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−75.5% from the high

₩4,315Today: ₩4,485 – ₩4,755₩18,570

Returns

  • 1W−4.1%
  • 1M−19.4%
  • 3M−18.4%
  • 6M−56.4%
  • YTD−68.0%
  • 1Y−75.6%
Volume today
9,446
0.6× the 20-day average
Traded today
₩43M
Listed shares
5,325,383
EPS (12 months)
₩202
Earnings yield 4.4%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

35Quiet
  • BuzzQuietBuzz 35 of 100 (50 is a normal day for this stock).
  • MomentumWeak-20% over the last month; the price is below its 20-day average.
  • News impactLow6 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

GFC Life Science stock overview

GFC Life Science (지에프씨생명과학, KRX: 388610) is listed on KOSDAQ, in the Chemicals sector. The company operates two business divisions. Its shares closed at ₩4,545 on Oct 27, 2026, down 2.68% on the day, giving it a market value of ₩24B.

Key facts

Market cap
₩24B
Sector
Chemicals
Latest price change
−2.68%
As of
Oct 27, 2026
Main business
The company operates two business divisions.

Quick answers about GFC Life Science

What does GFC Life Science do?
The company operates two business divisions. Its materials division develops and supplies cosmetic ingredients based on skin microbiome and exosome technologies to domestic and overseas customers, including skin booster products, plant-cell-based materials, peptides and hybrid exosome materials. Its clinical division provides human application tests that supply supporting evidence for functional cosmetics and advertising claims, and it manufactures at plants in Anseong and Dongtan.
What is the market cap of GFC Life Science?
The market capitalisation of GFC Life Science was ₩24B at the close on Oct 27, 2026.
Who are the largest shareholders of GFC Life Science?
According to the latest official filings, the largest reported holders are Kang Hee-chul (37.66%, as of Oct 23, 2026); BNB Asset Management (5.92%, as of Mar 9, 2026); D&T Investment (4.18%, as of Jul 10, 2025).
When is the next earnings report from GFC Life Science?
Korean companies rarely announce results dates in advance. Based on when GFC Life Science filed the same report in past years, its next 3q results is expected around Nov 14, 2026.

Company profile

The company operates two business divisions. Its materials division develops and supplies cosmetic ingredients based on skin microbiome and exosome technologies to domestic and overseas customers, including skin booster products, plant-cell-based materials, peptides and hybrid exosome materials. Its clinical division provides human application tests that supply supporting evidence for functional cosmetics and advertising claims, and it manufactures at plants in Anseong and Dongtan.

Written by AI from the company's latest annual report.

Korean name
지에프씨생명과학
Sector
Chemicals
Themes
—
CEO
강희철
Founded
Jun 2002
Listed
Jun 2025
Listed shares
5,325,383
Fiscal year ends
Month 12
Website
www.gfcos.co.kr/

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: GFC Life Science / 지에프씨생명과학 / 388610 / KRX:388610

Source: KRX statistical information